Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders

Xiangbo Yang,Zhijia Wang,Yuan Pei,Ning Song,Lei Xu,Bo Feng,Hanlin Wang,Xiaomin Luo,Xiaobei Hu,Xiaohui Qiu,Huijin Feng,Yaxi Yang,Yubo Zhou,Jia Li,Bing Zhou

DOI: https://doi.org/10.1016/j.ejmech.2021.113341

IF: 7.088

2021-06-01

European Journal of Medicinal Chemistry

Abstract:<p>SHP2, a non-receptor tyrosine phosphatase, plays a pivotal role in numerous oncogenic cell-signaling cascades like RAS-ERK, PI3K-AKT and JAK-STAT. On the other hand, proteolysis targeting chimera (PROTAC) has emerged as a promising strategy for the degradation of disease-related protein of interest (POI). SHP2 degradation via the PROTAC strategy will provide an alternative startegy for SHP2-mediated cancer therapy. Herein we described the design, synthesis and evaluation of a series of thalidomide-based heterobifunctional molecules and identified <strong>11</strong>(<strong>ZB-S-29</strong>) as the highly efficient SHP2 degrader with a DC₅₀ of 6.02nM. Further mechanism investigation illustrated that <strong>11</strong> came into function through targeted SHP2 protein degradation.</p>

chemistry, medicinal